Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Businessweek Archives

A Test For The Old Ticker Without The Treadmill


Developments to Watch

A TEST FOR THE OLD TICKER--WITHOUT THE TREADMILL

A stress test on a treadmill is the common way to diagnose coronary artery disease, but each year as many as a half-million Americans who are at risk cannot take the test because of lung disease, obesity, or frailty. The alternative has been angiography, a costly cardiac catheterization procedure. In early February, Du Pont Merck Pharmaceutical Co. will offer a new drug, IV Persantine, which simulates some of the effects of exercise--dilated arteries and increased blood flow--without forcing the patient onto the treadmill.

Patients would take the drug intravenously along with the radioactive thallium used in some stress tests. While it may not be suitable for those who have just had heart attacks or who have severe asthma, it's expected to find wide use. Du Pont Merck is licensing the drug, which has long been used to treat complications of heart valve replacements, from Boehringer Ingelheim International of Germany.EDITED BY WILLIAM D. MARBACH


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus